FDA Awards Priority Review Voucher to Sponsor of Rare Pediatric Disease Product TRIKAFTA

Summary

The FDA has issued a priority review voucher to Vertex Pharmaceutical, Inc., the manufacturer of TRIKAFTA, a rare pediatric disease product, following a review of the product's eligibility under the FD&C Act and FDASIA.